Skip to content
EvidenceBased
SavedSign in
Skip to content
EvidenceBased
outcomes / migraine frequency

Supplements for migraine frequency

Compared by effect and evidence certainty. Cost is not currently assessed, and nothing here is sold to you.

CoQ10grade Bmoderate certainty— Meta-analysis of RCTs: CoQ10 supplementation reduced migraine attack frequency (and, in some trials, duration) versus placebo; effect on migraine severity was less consistent. Trials are relatively small, so certainty is moderate rather than high.

Safety: no modeled interaction found; coverage unknown, not proven safe. Cost: not assessed. Evidence gaps: no major structured gap flagged; review the claim limitations.

Vitamin Dgrade Bmoderate certainty— Meta-analysis of 5 RCTs: vitamin D treatment significantly reduced headache days, attack frequency, headache severity, and migraine-related disability versus control in migraine patients. One of the more consistent positive signals for a vitamin D outcome in this dataset, though the evidence base is still just 5 trials.

Safety: minor — Magnesium is a cofactor in vitamin D metabolism; the two are complementary.. Cost: not assessed. Evidence gaps: no major structured gap flagged; review the claim limitations.

Magnesiumgrade Clow certainty— 10 oral-magnesium RCTs (n=789): reduced migraine frequency and intensity vs. placebo (odds ratios 0.20 and 0.27, no CIs given); some trials had inadequate randomization per the review authors. A separate IV arm covered acute attacks, not prevention.

Safety: minor — Generally fine with an SSRI; space about 2 hours apart.. Cost: not assessed. Evidence gaps: certainty or evidence strength remains limited.

Melatoningrade Clow certainty— Systematic review: melatonin showed promise for migraine prophylaxis, reducing attack frequency in several trials, with a tolerability profile comparable to or better than some standard preventives. The evidence base is small and heterogeneous.

Safety: uncertain — Melatonin with an SSRI: possible additive sedation; evidence is thin.. Cost: not assessed. Evidence gaps: certainty or evidence strength remains limited.